Vimarsana
Biggest News Aggregation in the World

Page 35 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer - Vimarsana News

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

Published: February 8, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaRegion FlamandeSharon ShachamVicky MakkerSelective Inhibitor Of Nuclear ExportEuropean Network For Gynaecological Oncological TrialLuxembourg Gynaecological Oncology GroupLeuven Cancer InstituteInternational Agency For Research On CancerKaryopharm Selective Inhibitor Of Nuclear ExportEuropean UnionAmerican Cancer SocietyInformation DepartmentKaryopharm Therapeutics IncDrug AdministrationWorld Health OrganizationExchange CommissionFoundation IncNation Cancer InstituteUniversity Of LeuvenMemorial Sloan Kettering Cancer CenterKaryopharm Therapeutics
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer - Vimarsana News

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

Published: February 8, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaRegion FlamandeSharon ShachamVicky MakkerSelective Inhibitor Of Nuclear ExportEuropean Network For Gynaecological Oncological TrialLuxembourg Gynaecological Oncology GroupLeuven Cancer InstituteInternational Agency For Research On CancerKaryopharm Selective Inhibitor Of Nuclear ExportEuropean UnionAmerican Cancer SocietyInformation DepartmentKaryopharm Therapeutics IncDrug AdministrationWorld Health OrganizationExchange CommissionFoundation IncNation Cancer InstituteUniversity Of LeuvenMemorial Sloan Kettering Cancer CenterKaryopharm Therapeutics
Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022 - Vimarsana News

Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022

Published: February 2, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

Source: prnewswire.com
Related Topics:
United KingdomSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncKaryopharm TherapeuticsSelective InhibitorNuclear ExportKaryopharm Therapeutics IncHealth Care Amp Hospitals Medical Pharmaceuticals Conference Call Announcements
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: February 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncCompensation Committee Of Karyopharm Board DirectorsKaryopharm TherapeuticsCompensation CommitteeNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm Therapeutics Inc
Karyopharm to Present at B. Riley Securities Oncology Investor Conference - Vimarsana News

Karyopharm to Present at B. Riley Securities Oncology Investor Conference

Published: January 21, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomRichard PaulsonSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncChief Executive OfficerSecurities Oncology InvestorSelective InhibitorNuclear ExportKaryopharm TherapeuticsKaryopharm Therapeutics IncHealth Care Amp Hospitals Medical Pharmaceuticals